Endogenous type-I interferon activity is not associated with depression or fatigue in systemic lupus erythematosus

Journal of Neuroimmunology

Volumn 223, Issue 1-2, 2010, Pages 13-19

  Kellner, Erinn S ^a   Lee, Pui Y ^a   Li, Yi ^a   Switanek, Juliana ^a   Zhuang, Haoyang ^a   Segal, Mark S ^a   Sobel, Eric S ^a,b   Satoh, Minoru ^a,b   Reeves, Westley H ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Depression; Fatigue; Systemic lupus erythematosus; Type I interferon

Indexed keywords

INTERFERON;

ADULT; AGED; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE PRODUCTION; DEPRESSION; DISEASE ASSOCIATION; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DEPRESSION; FATIGUE; FEMALE; HUMANS; INTERFERON TYPE I; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 77953538592     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.03.018     Document Type: Conference Paper

References (43)

1. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., Shark K.B., Grande W.J., Hughes K.M., Kapur V., Gregersen P.K., Behrens T.W. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2610-2615.
2. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry 1961, 4:561-571.
3. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 2003, 197:711-723.
4. Capuron L., Ravaud A., Neveu P.J., Miller A.H., Maes M., Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 2002, 7:468-473.
5. Capuron L., Neurauter G., Musselman D.L., Lawson D.H., Nemeroff C.B., Fuchs D., Miller A.H. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol. Psychiatry 2003, 54:906-914.
6. Da Costa D., Dritsa M., Bernatsky S., Pineau C., Menard H.A., Dasgupta K., Keschani A., Rippen N., Clarke A.E. Dimensions of fatigue in systemic lupus erythematosus: relationship to disease status and behavioral and psychosocial factors. J. Rheumatol. 2006, 33:1282-1288.
7. Dieperink E., Willenbring M., Ho S.B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am. J. Psychiatry 2000, 157:867-876.
8. Dieperink E., Ho S.B., Tetrick L., Thuras P., Dua K., Willenbring M.L. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen. Hosp. Psychiatry 2004, 26:237-240.
9. Eber T., Chapman J., Shoenfeld Y. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality?. Lupus 2005, 14:571-575.
10. Feng X., Wu H., Grossman J.M., Hanvivadhanakul P., FitzGerald J.D., Park G.S., Dong X., Chen W., Kim M.H., Weng H.H., Furst D.E., Gorn A., McMahon M., Taylor M., Brahn E., Hahn B.H., Tsao B.P. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006, 54:2951-2962.
11. Fragoso-Loyo H., Richaud-Patin Y., Orozco-Narvaez A., Davila-Maldonado L., Atisha-Fregoso Y., Llorente L., Sanchez-Guerrero J. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 2007, 56:1242-1250.
12. Gilli F., Sala A., Bancone C., Salacone P., Gallo M., Gaia E., Bertolotto A. Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients. J. Immunol. Meth. 2002, 262:187-190.
13. Gladman D.D., Urowitz M.B., Ong A., Gough J., MacKinnon A. A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). Lupus 1996, 5:190-195.
14. Harrison M.J., Ravdin L.D., Lockshin M.D. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum. 2006, 54:2515-2522.
15. Iverson G.L., Sawyer D.C., McCracken L.M., Kozora E. Assessing depression in systemic lupus erythematosus: determining reliable change. Lupus 2001, 10:266-271.
16. Janssen H.L., Brouwer J.T., van der Mast R.C., Schalm S.W. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J. Hepatol. 1994, 21:241-243.
17. Jonsen A., Bengtsson A.A., Nived O., Ryberg B., Truedsson L., Ronnblom L., Alm G.V., Sturfelt G. The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles. Lupus 2003, 12:846-850.
18. Jump R.L., Robinson M.E., Armstrong A.E., Barnes E.V., Kilbourn K.M., Richards H.B. Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J. Rheumatol. 2005, 32:1699-1705.
19. Kirou K.A., Lee C., George S., Louca K., Peterson M.G., Crow M.K. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005, 52:1491-1503.
20. Krupp L.B., LaRocca N.G., Muir J., Steinberg A.D. A study of fatigue in systemic lupus erythematosus. J. Rheumatol. 1990, 17:1450-1452.
21. Lapteva L., Nowak M., Yarboro C.H., Takada K., Roebuck-Spencer T., Weickert T., Bleiberg J., Rosenstein D., Pao M., Patronas N., Steele S., Manzano M., van der Veen J.W., Lipsky P.E., Marenco S., Wesley R., Volpe B., Diamond B., Illei G.G. Anti-N-methyl-d-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 2006, 54:2505-2514.
22. Lee P.Y., Reeves W.H. Type I interferon as a target of treatment in SLE. Endocr. Metab. Immune Disord. Drug Targets 2006, 6:323-330.
23. Lee P.Y., Li Y., Richards H.B., Chan F.S., Zhuang H., Narain S., Butfiloski E.J., Sobel E.S., Reeves W.H., Segal M.S. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 2007, 56:3759-3769.
24. Lin J.M., Brimmer D.J., Maloney E.M., Nyarko E., Belue R., Reeves W.C. Further validation of the Multidimensional Fatigue Inventory in a US adult population sample. Popul. Health Metr. 2009, 7:18.
25. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998, 339:1485-1492.
26. Omdal R., Brokstad K., Waterloo K., Koldingsnes W., Jonsson R., Mellgren S.I. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur. J. Neurol. 2005, 12:392-398.
27. Pertovaara M., Hasan T., Raitala A., Oja S.S., Yli-Kerttula U., Korpela M., Hurme M. Indoleamine 2, 3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin. Exp. Immunol. 2007, 150:274-278.
28. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 2004, 202:8-32.
29. Raison C.L., Borisov A.S., Majer M., Drake D.F., Pagnoni G., Woolwine B.J., Vogt G.J., Massung B., Miller A.H. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol. Psychiatry 2009, 65:296-303.
30. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., Spivey J.R., Saito K., Miller A.H. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 2009.
31. Reeves W.H., Narain S., Satoh M. Autoantibodies in systemic lupus erythematosus. Arthritis and Allied Conditions, A Textbook of Rheumatology 2004, 1497-1521. Lippincott Williams & Wilkins, Philadelphia. W.J. Koopman (Ed.).
32. Schaefer M., Engelbrecht M.A., Gut O., Fiebich B.L., Bauer J., Schmidt F., Grunze H., Lieb K. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:731-746.
33. Schneebaum A.B., Singleton J.D., West S.G., Blodgett J.K., Allen L.G., Cheronis J.C., Kotzin B.L. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am. J. Med. 1991, 90:54-62.
34. Shiozawa S., Kuroki Y., Kim M., Hirohata S., Ogino T. Interferon-alpha in lupus psychosis. Arthritis Rheum. 1992, 35:417-422.
35. Shortall E., Isenberg D., Newman S.P. Factors associated with mood and mood disorders in SLE. Lupus 1995, 4:272-279.
36. Smets E.M., Garssen B., Bonke B., De Haes J.C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 1995, 39:315-325.
37. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., Schaller J.G., Talal N., Winchester R.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25:1271-1277.
38. Teh L.S., Bedwell A.E., Isenberg D.A., Gordon C., Emery P., Charles P.J., Harper M., Amos N., Williams B.D. Antibodies to protein P in systemic lupus erythematosus. Ann. Rheum. Dis. 1992, 51:489-494.
39. Veenhof C.H., de Wit R., Taal B.G., Dirix L.Y., Wagstaff J., Hensen A., Huldij A.C., Bakker P.J. A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour. Eur. J. Cancer 1992, 28:75-78.
40. Wang B., Gladman D.D., Urowitz M.B. Fatigue in lupus is not correlated with disease activity. J. Rheumatol. 1998, 25:892-895.
41. Weimar W., Heijtink R.A., ten Kate F.J., Schalm S.W., Masurel N., Schellekens H., Cantell K. Double-blind study of leucocyte interferon administration in chronic HBsAg-positive hepatitis. Lancet 1980, 1:336-338.
42. Widner B., Sepp N., Kowald E., Ortner U., Wirleitner B., Fritsch P., Baier-Bitterlich G., Fuchs D. Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology 2000, 201:621-630.
43. Zhuang H., Narain S., Sobel E., Lee P.Y., Nacionales D.C., Kelly K.M., Richards H.B., Segal M., Stewart C., Satoh M., Reeves W.H. Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin. Immunol. 2005, 117:238-250.